


contd.
a2
nicotinic acetylcholine activating effective amount of a compound
as claimed in claim 9 or pharmaceutically acceptable salts
thereof.--

REMARKS

It is respectfully requested that the above amendments be entered prior to calculation of the filing fee and prior to examination. The claims have been amended to correct improper numbering and to place them in better form for U.S. practice. No new matter has been added.

If there are any questions regarding this amendment or the application in general, a telephone call to the undersigned would be appreciated since this should expedite the prosecution of the application for all concerned.

Respectfully submitted,



Herbert I. Cantor
Registration No. 24,392

August 22, 2001

CROWELL & MORING, LLP
P.O. Box 14300
Washington, DC 20044-4300
Telephone No.: (202) 628-8800
Facsimile No.: (202) 628-8844

APPENDIX

Please amend Claim 8 as follows:

--8. (Amended) [The use of the compounds] A method of activating $\alpha 4\beta 2$ nicotinic acetylcholine receptors comprising administering an $\alpha 4\beta 2$ nicotinic acetylcholine activating effective amount of a compound as claimed in claim 1 or pharmaceutically acceptable salts thereof [as the activators for $\alpha 4\beta 2$ nicotinic acetylcholine receptors].--

Please amend the second Claim 8 appearing on page 58 as follows:

[8] 17. (Amended) [The use of the compounds] A method of activating $\alpha 4\beta 2$ nicotinic acetylcholine receptors comprising administering an $\alpha 4\beta 2$ nicotinic acetylcholine activating effective amount of a compound as claimed in claim 9 or pharmaceutically acceptable salts thereof [as the activators for $\alpha 4\beta 2$ nicotinic acetylcholine receptors].--